Jazz Pharmaceuticals PLC (JAZZ) Stock Price Down 2%
Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 2% during trading on Monday . The stock traded as low as $119.52 and last traded at $120.84, with a volume of 852,900 shares. The stock had previously closed at $123.31.
Several analysts recently commented on the company. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Saturday, June 18th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $186.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Thursday, May 12th. Mizuho raised Jazz Pharmaceuticals PLC from a “neutral” rating to a “buy” rating and raised their target price for the stock from $137.00 to $193.00 in a report on Wednesday, May 11th. SunTrust Banks Inc. reaffirmed a “buy” rating and set a $210.00 target price (up from $200.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, June 2nd. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $185.25.
The company has a market cap of $7.31 billion and a PE ratio of 21.24. The company has a 50-day moving average price of $139.06 and a 200 day moving average price of $139.40.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.80 by $0.17. During the same period in the previous year, the company posted $2.41 earnings per share. The business earned $381 million during the quarter, compared to analysts’ expectations of $376.40 million. The firm’s revenue was up 14.2% compared to the same quarter last year. Analysts forecast that Jazz Pharmaceuticals PLC will post $10.08 EPS for the current year.
In other Jazz Pharmaceuticals PLC news, Director Rick E. Winningham sold 633 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $136.45, for a total transaction of $86,372.85. Following the transaction, the director now owns 15,391 shares in the company, valued at approximately $2,100,101.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Seamus Mulligan sold 27,968 shares of the business’s stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $128.32, for a total value of $3,588,853.76. Following the transaction, the director now owns 1,072,411 shares in the company, valued at approximately $137,611,779.52. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Jazz Pharmaceuticals PLC stock. I.G. Investment Management LTD. raised its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 0.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 20,182 shares of the specialty pharmaceutical company’s stock after buying an additional 108 shares during the period. I.G. Investment Management LTD.’s holdings in Jazz Pharmaceuticals PLC were worth $2,837,000 as of its most recent filing with the SEC.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.